Lung Cancer Gene Panel by NGS (SNVs, InDels & Fusions) + PD-L1 (SP263) by IHC in Howrah

The Lung Cancer gene Panel by NGS, combined with PD-L1 (SP263) testing by IHC, represents a state-of-the-art approach to comprehensively assess lung cancer patients' genetic profiles for precise diagnosis and treatment. This cutting-edge genetic test employs next-generation sequencing (NGS) to meticulously examine a spectrum of crucial genes linked to lung cancer, offering invaluable insights into therapeutic, prognostic, and diagnostic aspects.

The panel covers a wide range of lung cancer-associated genes, including EGFR, BRAF, MET (with a focus on exon 14 skipping), RET, ERBB2, KRAS, ALK, ROS1, and NTRK1, NTRK2, NTRK3 fusions. It scrutinizes these genes for various genomic alterations such as single nucleotide variants (SNVs), small insertions/deletions (InDels), copy number variations (CNVs), and gene fusions.

With a minimum sequencing depth of 250X on a rigorously validated Illumina platform, the Lung Panel ensures unparalleled accuracy. The subsequent annotation process, following AMP-ASCO-CAP guidelines, prioritizes and categorizes reportable genomic alterations and fusion events meticulously.

Furthermore, PD-L1 testing is performed using Ventana PD-L1 (SP263) platform, which provides critical information for immunotherapy decisions in lung cancer patients, particularly those being considered for first-line treatment with pembrolizumab based on high PD-L1 expression levels. Together, these advanced technologies empower clinicians to tailor precise treatment strategies for lung cancer patients.

Disclaimer: In no event shall the liability of TATA 1MG exceed the amount of actual cost of test charges incurred by the customer as stated on the invoice issued by Tata 1mg.